Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of elénzia CONTROL® on Weight and Metabolic Health in Adults Naïve to or Who Have Recently Discontinued Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use

NCT07789223 is registered in ClinicalTrials.gov with Elenzia as lead sponsor.

NCT NCT07789223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of elénzia CONTROL® on Weight and Metabolic Health in Adults Naïve to or Who Have Recently Discontinued Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use
Lead sponsor
Elenzia
Phase
Not applicable
Overall status
Recruiting
Start date
September 15, 2026
Completion date
February 28, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, weight maintenance